On Tuesday, VolitionRX Ltd (AMEX: VNRX) was 8.42% up from the session before settling in for the closing price of $0.29. A 52-week range for VNRX has been $0.22 – $0.94.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 5.38%. When this article was written, the company’s average yearly earnings per share was at 33.55%. With a float of $97.40 million, this company’s outstanding shares have now reached $109.62 million.
VolitionRX Ltd (VNRX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward VolitionRX Ltd stocks. The insider ownership of VolitionRX Ltd is 20.69%, while institutional ownership is 21.29%. The most recent insider transaction that took place on Nov 17 ’25, was worth 7,000. In this transaction President and CEO of this company bought 20,000 shares at a rate of $0.35, taking the stock ownership to the 2,554,847 shares. Before that another transaction happened on Oct 14 ’25, when Company’s President and CEO bought 110,000 for $0.51, making the entire transaction worth $56,100. This insider now owns 2,534,847 shares in total.
VolitionRX Ltd (VNRX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.06 earnings per share (EPS) during the time that was less than consensus figure (set at -0.05) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.55% per share during the next fiscal year.
VolitionRX Ltd (AMEX: VNRX) Trading Performance Indicators
You can see what VolitionRX Ltd (VNRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.23, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.11 in one year’s time.
